Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2017-09-14 Board/Management Inform…
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Board Change
Board/Management Information Classification · 98% confidence The document explicitly states 'RNS Number : 6956Q' and contains an announcement regarding a 'Board Change' (resignation of CFO and appointment of interim CFO). This type of corporate event disclosure, especially when originating from the London Stock Exchange's news service (indicated by 'RNS Number' and 'The company news service from the London Stock Exchange'), falls under the category of general regulatory announcements. Since the specific event (Board Change) is not covered by a more precise code like DIRS (Director's Dealing) or DEF 14A (Remuneration), the most appropriate classification is the general regulatory filing category, RNS.
2017-09-14 English
US Composition of Matter Patent Allowed
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated 06 September 2017. It explicitly states 'THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details the allowance of a US composition of matter patent for their product Feraccru®. This structure and content strongly indicate a regulatory news service announcement. Since the announcement is about Intellectual Property (IP) protection, the most specific category is 'Intellectual Property' (IP). However, given the format is a direct RNS release, and IP is a specific topic, I must check the definitions. 'IP' (Intellectual Property) is defined as 'IP'. The document is a direct announcement of an IP milestone (patent allowance), not a general regulatory filing fallback (RNS). Therefore, 'IP' is the most appropriate classification.
2017-09-06 English
Shield to Present at Baird Healthcare Conference
Regulatory Filings Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 3693P' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces that the CEO will present at an external conference (Baird Global Healthcare Conference) and provides details about the presentation topic and webcast access. This is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, ER) or a specific corporate action announcement (like DIV, CAP, DIRS). Since it is a general regulatory announcement that doesn't fit the other specific categories, the fallback code 'RNS' is appropriate.
2017-08-31 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is very short (2547 characters) and its primary purpose, as stated in the title and body, is to announce that the company 'will report its interim results for the six months ended 30 June 2017 on Wednesday 20 September 2017.' It also mentions hosting a presentation/conference call. This structure—announcing the future release date of a report (Interim Results) rather than containing the full results or the report itself—fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it a general regulatory filing (RNS) since a more specific category (RPA) applies based on the 'MENU VS MEAL' rule.
2017-08-15 English
Grant of Share Options
Remuneration Information Classification · 99% confidence The document is an announcement dated July 11, 2017, originating from Shield Therapeutics plc, identified by the 'RNS Number : 7531K'. The content explicitly details the 'Grant of Share Options' to PDMRs (Persons Discharging Managerial Responsibilities) under incentive plans (LTIP and CSOP). This type of filing, which reports personal share transactions or option grants involving directors/executives, falls under the category of Director's Dealing (DIRS). Although it involves options, the core regulatory requirement being met is the disclosure of insider transactions/holdings changes, not a general capital change (SHA) or remuneration report (DEF 14A).
2017-07-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly identified as an 'RNS Number' notification and uses the 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The filing date is 10 July 2017, and it details the percentage change in voting rights held by Aviva plc and its subsidiaries, crossing a notification threshold. This aligns perfectly with the 'Major Shareholding Notification' category (MRQ). Although it is an RNS filing, MRQ is the more specific classification.
2017-07-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.